vs

Side-by-side financial comparison of Arcturus Therapeutics Holdings Inc. (ARCT) and VerifyMe, Inc. (VRME). Click either name above to swap in a different company.

Arcturus Therapeutics Holdings Inc. is the larger business by last-quarter revenue ($7.2M vs $5.0M, roughly 1.4× VerifyMe, Inc.). On growth, VerifyMe, Inc. posted the faster year-over-year revenue change (-7.4% vs -68.4%). Over the past eight quarters, VerifyMe, Inc.'s revenue compounded faster (-5.2% CAGR vs -56.5%).

Arcturus Therapeutics Holdings Inc. is an American RNA medicines biotechnology company focused on the discovery, development and commercialization of therapeutics for rare diseases and infectious diseases. Arcturus has developed proprietary lipid nanoparticle RNA therapeutics for nucleic acid medicines including small interfering RNA (siRNA), messenger RNA (mRNA), gene editing RNA, DNA, antisense oligonucleotides, and microRNA.

VerifyMe, Inc. is a technology provider specializing in identity verification, anti-counterfeiting, and brand protection solutions. Its offerings include secure authentication tools, supply chain traceability systems, and customer engagement platforms, serving consumer goods, pharmaceutical, and retail sectors across North America and select global markets.

ARCT vs VRME — Head-to-Head

Bigger by revenue
ARCT
ARCT
1.4× larger
ARCT
$7.2M
$5.0M
VRME
Growing faster (revenue YoY)
VRME
VRME
+61.0% gap
VRME
-7.4%
-68.4%
ARCT
Faster 2-yr revenue CAGR
VRME
VRME
Annualised
VRME
-5.2%
-56.5%
ARCT

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
ARCT
ARCT
VRME
VRME
Revenue
$7.2M
$5.0M
Net Profit
$-3.4M
Gross Margin
41.2%
Operating Margin
-68.2%
Net Margin
-66.7%
Revenue YoY
-68.4%
-7.4%
Net Profit YoY
3.1%
-38.4%
EPS (diluted)
$-0.26

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ARCT
ARCT
VRME
VRME
Q4 25
$7.2M
Q3 25
$17.2M
$5.0M
Q2 25
$28.3M
$4.5M
Q1 25
$29.4M
$4.5M
Q4 24
$22.8M
Q3 24
$41.7M
$5.4M
Q2 24
$49.9M
$5.4M
Q1 24
$38.0M
$5.8M
Net Profit
ARCT
ARCT
VRME
VRME
Q4 25
Q3 25
$-13.4M
$-3.4M
Q2 25
$-9.2M
$-291.0K
Q1 25
$-14.1M
$-571.0K
Q4 24
$-30.0M
Q3 24
$-6.9M
$-2.4M
Q2 24
$-17.2M
$-346.0K
Q1 24
$-26.8M
$-553.0K
Gross Margin
ARCT
ARCT
VRME
VRME
Q4 25
Q3 25
41.2%
Q2 25
35.2%
Q1 25
33.4%
Q4 24
Q3 24
34.9%
Q2 24
39.1%
Q1 24
39.2%
Operating Margin
ARCT
ARCT
VRME
VRME
Q4 25
Q3 25
-96.3%
-68.2%
Q2 25
-41.0%
-7.1%
Q1 25
-57.3%
-13.3%
Q4 24
-146.7%
Q3 24
-25.8%
-52.8%
Q2 24
-42.4%
-10.0%
Q1 24
-80.0%
-11.2%
Net Margin
ARCT
ARCT
VRME
VRME
Q4 25
Q3 25
-78.4%
-66.7%
Q2 25
-32.4%
-6.4%
Q1 25
-47.9%
-12.8%
Q4 24
-131.8%
Q3 24
-16.6%
-44.6%
Q2 24
-34.5%
-6.5%
Q1 24
-70.5%
-9.6%
EPS (diluted)
ARCT
ARCT
VRME
VRME
Q4 25
Q3 25
$-0.49
$-0.26
Q2 25
$-0.34
$-0.02
Q1 25
$-0.52
$-0.05
Q4 24
$-1.10
Q3 24
$-0.26
$-0.23
Q2 24
$-0.64
$-0.03
Q1 24
$-1.00
$-0.05

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ARCT
ARCT
VRME
VRME
Cash + ST InvestmentsLiquidity on hand
$230.9M
Total DebtLower is stronger
Stockholders' EquityBook value
$214.0M
$11.1M
Total Assets
$271.1M
$13.3M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ARCT
ARCT
VRME
VRME
Q4 25
$230.9M
Q3 25
$180.4M
Q2 25
$196.5M
Q1 25
$216.9M
Q4 24
$237.0M
Q3 24
$237.2M
$2.6M
Q2 24
$260.3M
$2.9M
Q1 24
$288.4M
$2.8M
Total Debt
ARCT
ARCT
VRME
VRME
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$500.0K
Q2 24
$600.0K
Q1 24
$800.0K
Stockholders' Equity
ARCT
ARCT
VRME
VRME
Q4 25
$214.0M
Q3 25
$224.6M
$11.1M
Q2 25
$231.1M
$14.4M
Q1 25
$233.8M
$14.6M
Q4 24
$241.0M
Q3 24
$261.9M
$10.3M
Q2 24
$258.6M
$12.3M
Q1 24
$264.0M
$12.4M
Total Assets
ARCT
ARCT
VRME
VRME
Q4 25
$271.1M
Q3 25
$282.3M
$13.3M
Q2 25
$309.3M
$17.2M
Q1 25
$331.8M
$17.1M
Q4 24
$344.1M
Q3 24
$370.7M
$14.8M
Q2 24
$388.6M
$17.5M
Q1 24
$418.8M
$17.9M
Debt / Equity
ARCT
ARCT
VRME
VRME
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.05×
Q2 24
0.05×
Q1 24
0.06×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ARCT
ARCT
VRME
VRME
Operating Cash FlowLast quarter
$-74.3M
$243.0K
Free Cash FlowOCF − Capex
$-74.5M
FCF MarginFCF / Revenue
-1035.2%
Capex IntensityCapex / Revenue
3.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ARCT
ARCT
VRME
VRME
Q4 25
$-74.3M
Q3 25
$-17.2M
$243.0K
Q2 25
$-5.8M
$710.0K
Q1 25
$-35.1M
$-404.0K
Q4 24
$-284.0K
Q3 24
$-23.8M
$-10.0K
Q2 24
$-30.1M
$372.0K
Q1 24
$-5.6M
$-60.0K
Free Cash Flow
ARCT
ARCT
VRME
VRME
Q4 25
$-74.5M
Q3 25
$-17.3M
Q2 25
Q1 25
$-35.3M
Q4 24
Q3 24
$-23.8M
$-12.0K
Q2 24
$-30.5M
$369.0K
Q1 24
$-5.8M
$-62.0K
FCF Margin
ARCT
ARCT
VRME
VRME
Q4 25
-1035.2%
Q3 25
-101.1%
Q2 25
Q1 25
-120.1%
Q4 24
Q3 24
-57.2%
-0.2%
Q2 24
-61.1%
6.9%
Q1 24
-15.3%
-1.1%
Capex Intensity
ARCT
ARCT
VRME
VRME
Q4 25
3.2%
Q3 25
1.1%
Q2 25
0.0%
Q1 25
0.5%
Q4 24
0.0%
Q3 24
0.2%
0.0%
Q2 24
0.7%
0.1%
Q1 24
0.6%
0.0%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ARCT
ARCT

Segment breakdown not available.

VRME
VRME

Proactive Services$4.2M83%
Other$869.0K17%

Related Comparisons